FDA Panel Issues Split-Decision for Gilead’s HIV Prevention Drug

August 9, 2019

The FDA’s Antimicrobial Drugs Advisory Committee voted Wednesday to recommend Gilead Sciences’ supplemental NDA for Descovy (emtricitabine and tenofovir alafenamide ) for prevention of  HIV-1 infections in men and transgender women — but shot down the drug for use in cisgender women.

The committee voted 16-2 in favor of the sNDA for pre-exposure prophylaxis (PrEP) for men and transgender women and 10-8 against the indication for cisgender women.

The committee considered the results of the DISCOVER trial, which compared the efficacy of the drug to Truvada (emtricitabine and tenofovir disoproxil fumarate).

View today's stories